
price close busi februari
biomed devic servic
full steam ahead earli stage robust multi-
bottom line reiter buy rate follow unequivoc strong finish
expect except growth continu support
strong growth sensor volum continu ww adopt cgm on-going
launch move addit ou territori medicar
stock expens ev/sal remain bullish
near- long-term product pipelin opportun cgm util permeat
 popul eventu use broader diagnost tool ye abbott
competit remain overhang throughout particularli
respect icgm design howev continu roll across global
geographi recommend investor view abbott libre-rel volatil buy
opportun view one best pure growth asset across med-tech
buy pt
result releas revenu y/i
y/i respect in-lin preliminari figur disclos
earli januari revenu came cg expect
consensu us sale benefit increas market
awar accept cgm led acceler medicar
commerci channel manag continu highlight dtc advertis includ
libr help drive broader patient awar cgm someth
expect continu gm slightli estim
y/i channel geograph mix impact y/i line
except start manag highlight robust demand new
system support improv market awar accept cgm
biggest constraint near-term patient addit appear manag abil
suppli fulfil new patient demand given unpreced demand new
exist patient addit manag note us patient cover
pharmaci channel lower barrier adopt patient
physician come expens near-term revenu tune
headwind ntm note come broadli in-lin previou guidanc
start year alreadi reflect forward estim
ou growth xfx ou impress reimburs tailwind
strength key direct sale market manag highlight signific
ou busi make total revenu reiter plan continu
invest ou commerci infrastructur highlight recent entri apac
includ korea japan well continu execut germani
continu invest futur growth manag note plan restructur
custom support team effort optim current futur growth
specif incur charg build new
facility/team philippin elimin team us addit
highlight capital-expenditure primarili relat manufactur
expans doubl capac az well prepar
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
guidanc chang estim
re-affirmed revenu guidanc manag
expect growth support sensor volum ou expans ww
instal base gross margin guidanc given approxim non-gaap
opex expect non-gaap adjust ebitda margin
made follow chang estim
figur summari estim revis
high-growth med-tech comp group current trade mean ev/sal multipl
estim revenu sum increas price target base
ev/sal multipl appli revenu estim
price target assum cash debt share
outstand
figur matrix discount rate impli share price target
buy unchang target price februari
biomed devic servic
except ep newold newold newold product comp ev/sal multipl price metric use ev/sal valuat growth medic devic ev/sal multipl sale share outstand figur dexcom incom statement
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price februari
biomed devic servic
canaccord genuiti estim compani report compani report
buy unchang target price februari
biomed devic servic
